Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2024Frontiers in HematologyOpen Access

Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network

View Full Paper
Ask AI
Bookmark
Share

Authors

VFVittorio Del FabroUniversità degli Studi di Enna KoreUMUroš MarkovicAzienda Universitaria Ospedaliera Consorziale - Policlinico BariSFSara FrazzettoUniversity of Catania

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fabro et al. (2024) studied this question.

synapsesocial.com/papers/68e64045b6db6435875d1b06https://doi.org/10.3389/frhem.2024.1425677
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop2012 · 280 citations
  2. 2Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects2002 · 129 citations
  3. 3MYD 88 L265P and CXCR 4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity2015 · 102 citations
  4. 4American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer2010 · 45 citations
  5. 5Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey2021 · 12 citations